-
Clinical Trials & Development6 days agoESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop...
-
Clinical Trials & Development6 days agoESMO 2026: Marengo’s bispecific antibody shrinks 8 tumor types in Phase 2
Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous...
-
Clinical Trials & Development6 days agoFDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no...
-
Clinical Trials & Development6 days agoRoche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
Roche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional...
-
Clinical Trials & Development6 days agoSTAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.
-
Clinical Trials & Development6 days agoAbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed...
-
Clinical Trials & Development7 days agoAbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and...
-
Clinical Trials & Development7 days agoSTAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
-
Clinical Trials & Development7 days agoSTAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed market expectations.
-
Clinical Trials & Development7 days agoComplex Innovative Trial Design Meeting Program
As displayed in the Federal Register notice on August 1, 2018, FDA is conducting a Complex Innovative Designs (CID) Meeting Program to support the goal of...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
